Compare Entegris Inc (ENTG) vs 10X Genomics Inc (TXG) Price & Performance

ENTG trades at $166.32, down 0.34% on the day, with strong technical momentum showing bullish moving averages and key resistance at $168. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected October 29. Revenue remains stable at $3.2B (2025) with improving net margins from 5.12% (2023) to 7.37% (2025), though valuation ratios appear elevated with P/E at 83.16.

Wall Street maintains strong bullish sentiment with 70% buy ratings and $182.43 consensus price target, representing 9.7% upside. Key risks include high debt levels ($3.98B) and semiconductor industry cyclicality. The upcoming Q3 earnings and November Investor Day will be critical catalysts for near-term direction.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.